M&A

July 6, 2021

Supersize That Buyout

Mid-sized companies are making money moves in the mergers and acquisitions (M&A) space. 🤑

Usually, large cap pharma companies order smaller pharmas for takeout— take Gilead’s deal to buy Immunomedics. Gilead dropped over $21B. Large caps are slowing down on big deals, though. 

Companies like Jazz Pharmaceuticals, Horizon Therapeutics, and MorphoSys are starting to play. 😈 Mid caps made over $13B in M&A deals this year. That’s roughly on-par with large caps’ expenditures over the same period. 

Why, you ask? M&A ensures pharmas have products to sell. 💸 And if the deal flow is any indication, mid-sized pharma aspires for growth to make them more than mid-sized… 

Learn More About...

You Might Also Enjoy

Crypto

January 8, 2024

Crypto’s Confidence Continues

Cryptocurrencies are off to a strong start this week, as optimism around the spot Bitcoin ETF decision by the Securities & Exchange Commission (SEC) continues. 👀

Nearly a dozen fund companies have filed the necessary paperwork to launch this investment vehicle. However, last week, the SEC requested asset managers make “minor” changes to their filings to disclose fees or identities of the market-makers for their ETFs. 📝

Read It

Earnings

January 9, 2024

Samsung Slashes Profit Expectations

Shares of Samsung Electronics fell today after the consumer electronics giant warned about its fourth-quarter results. It now expects a 35% YoY decline in operating profit during the fourth quarter of 2023, coming in at 2.8 trillion South Korean won vs. 4.31 trillion a year ago. 🔻

Given it is the country’s largest company and the world’s largest maker of dynamic random-access memory chips, analysts closely watch it as a bellwether for the consumer electronics industry. 👀

Read It

M&A

February 20, 2024

Walgreens Gets The Boot

It’s tough being part of the U.S. stock market’s largest indexes. With thousands of individual stocks to choose from, if any one component isn’t performing, it’s simply replaced by something else. 🔀

In other words, everyone is replaceable. That’s the harsh truth that Walgreens is facing today after discovering Amazon is replacing it in the Dow Jones Industrial Average. 🔀

Read It

More in   M&A

View All

M&A

October 6, 2023

Exxon Mobil Nears Megadeal

Exxon Mobil is closing in on a blockbuster takeover of Pioneer Natural Resources, with the $60 billion acquisition potentially reshaping the U.S. oil industry. 🛢️

After posting a record profit in 2022, the oil giant has been looking for ways to put that cash to work. It’s also been eyeing the oil-rich Permian Basin of West Texas and New Mexico, a region it says is critical to its growth plans.

Read It

M&A

December 11, 2023

An M&A Mashup

It was another busy Monday of M&A and fundraising news, so let’s quickly recap. 👇

First up is Macy’s, which saw shares soar 20% on reports that the 165-year-old retailer is considering a buyout offer from Arkhouse Management and Brigade Capital Management. It’s unclear how the company’s board feels about the offer, but clearly, these firms have value in Macy’s real estate. Analysts speculate that the investor group may sell off real estate and spin off its e-commerce business to deliver short-term gains. However, that would come at the expense of the core retail business people know and love it for. 🏬

Read It

M&A

January 8, 2024

Biotech Builds Buyout Momentum

It was another busy Monday of M&A activity in the biotech and healthcare space, with more expected during this week’s annual JPMorgan Healthcare Conference. Let’s quickly recap today’s deals. 📝

Johnson & Johnson will acquire cancer drug developer Ambrx Biopharma for $2 billion in cash. Ambrx is aiming to target multiple cancers with drugs called antibody-drug conjugates, or ADCs, which are described by researchers as “guided missiles” to directly target and kill cancer cells while limiting damage to healthy cells. 🎯

Read It